CARLOMAGNO, FRANCESCA
CARLOMAGNO, FRANCESCA
DIPARTIMENTO DI MEDICINA MOLECOLARE E BIOTECNOLOGIE MEDICHE
Molecular mechanisms of RET activation in human cancer
2002 Santoro, Massimo; Melillo, Rosa Marina; Carlomagno, F; Fusco, Alfredo; Vecchio, Giancarlo
Ret-mediated mitogenesis requires Src kinase activity.
1999 Melillo, Rosa Marina; Barone, Mv; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, Alfredo; Santoro, Massimo
Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
1996 Carlomagno, F; De Vita, G; Berlingieri, Mt; De Franciscis, V; Melillo, Rosa Marina; Colantuoni, V; Kraus, Mh; Di Fiore, Pp; Fusco, Alfredo; M., Santoro
Different mutations of the RET gene cause different human tumoral diseases.
1999 Santoro, M.; Melillo, R. M.; Carlomagno, F.; Visconti, Roberta; DE VITA, Gabriella; Salvatore, Giuliana; Fusco, A.; Vecchio, Giancarlo
Ret-mediated mitogenesis requires Src kinase activity.
1999 Melillo, R. M.; Barone, M. V.; Lupoli, Gelsy; Cirafici, A. M.; Carlomagno, F.; Visconti, Roberta; Matoskova, B.; DI FIORE, P. P.; Vecchio, Giancarlo; Fusco, A.; Santoro, M.
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret
1998 Chiariello, M; Visconti, R; Carlomagno, Francesca; Melillo, Rosa Marina; Bucci, C; De Franciscis, V; Fox, Gm; Jing, S; Coso, Om; Gutkind, Sj; Fusco, Alfredo; Santoro, M.
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
2003 Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo
The extent of linkage disequilibrium in four populations with distinct demographic histories
2000 Dunning, Am; Durocher, F; Healey, Cs; Teare, Md; Mcbride, Se; Carlomagno, Francesca; Xu, Cf; Dawson, E; Rhodes, S; Ueda, S; Lai, E; Luben, Rn; VAN RENSBURG, Ej; Mannermaa, A; Kataja, V; Rennart, G; Dunhami, ; Purvis, I; Easton, D; Ponder, Ba
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival
2000 De Vita, Gabriella; Melillo, Rosa Marina; Carlomagno, Francesca; Visconti, R; Castellone, Md; Bellacosa, A; Billaud, M; Fusco, Alfredo; Tsichlis, Pn; Santoro, M.
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease
1998 Carlomagno, F.; Melillo, Rosa Marina; Visconti, R.; Salvatore, G.; De Vita, Gabriella; Lupoli, G.; Yu, Y. B.; Jing, S. Q.; Vecchio, Giancarlo; Fusco, Alfredo; Santoro, M.
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer
2012 Gnanaprakasam, Krisnamoorthy; Guida, Teresa; Visciano, Carla; Liotti, Federica; Carlomagno, Francesca; Melillo, ROSA MARINA
Molecular Mechianism of RET Activation In Human Neoplasia
2002 Santoro, Massimo; Carlomagno, F.; Melillo, ROSA MARINA; Vecchio, Giancarlo; Fusco, Alfredo
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas
2003 Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; Castellone, MARIA DOMENICA; Vitagliano, Donata; Guida, Teresa; Vecchio, Giancarlo; Fusco, Alfredo
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes
2002 Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Napolitano, M.; Vecchio, Giancarlo; Fusco, Alfredo; Gazit, A.; Levitzki, A.; Santoro, Massimo
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene.
2006 Iavarone, C; Acunzo, M; Carlomagno, Francesca; Catania, A; Melillo, ROSA MARINA; Carlomagno, MARIA STELLA; Santoro, Massimo; Chiariello, M.
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
1998 G., Tallini; Santoro, Massimo; M., Helie; Carlomagno, Francesca; G., Salvatore; G., Chiappetta; M. L., Carcangiu; Fusco, Alfredo
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
1993 M., Santoro; N., Sabino; Y., Ishizaka; T., Ushijima; Carlomagno, Francesca; A., Cerrato; M., Grieco; C., Battaglia; M. L., Martelli; C., Paulin
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE
1992 Santoro, Massimo; Carlomagno, Francesca; Hay, I. D.; Herrmann, M. A.; Grieco, M.; Melillo, ROSA MARINA; Pierotti, M. A.; Bongarzone, I.; DELLA PORTA, G.; Berger, N.; Peix, J. L.; Paulin, C.; Fabien, N.; Vecchio, Giancarlo; Jenkins, R. B.; Fusco, Alfredo
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor.
2003 Ciardiello, F; Caputo, R; Damiano, Vincenzo; Caputo, R; Troiani, T; Vitagliano, D; Carlomagno, F; Veneziani, BIANCA MARIA; Fontanini, G; Bianco, Ar; Tortora, Giampaolo
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
2003 Fortunato, Ciardiello; Rosa, Caputo; Vincenzo, Damiano; Roberta, Caputo; Teresa, Troiani; Donatella, Vitagliano; Carlomagno, Francesca; Veneziani, BIANCA MARIA; Gabriella, Fontanini; A., Raffaele Bianco; Giampaolo, Tortora
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Molecular mechanisms of RET activation in human cancer | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Santoro, Massimo; Melillo, Rosa Marina; Carlomagno, F; Fusco, Alfredo; Vecchio, Giancarlo | |
| Ret-mediated mitogenesis requires Src kinase activity. | 1.1 Articolo in rivista | 1999 | Melillo, Rosa Marina; Barone, Mv; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, Alfredo; Santoro, Massimo | |
| Molecular heterogeneity of RET loss of function in Hirschsprung's disease. | 1.1 Articolo in rivista | 1996 | Carlomagno, F; De Vita, G; Berlingieri, Mt; De Franciscis, V; Melillo, Rosa Marina; Colantuoni, V; Kraus, Mh; Di Fiore, Pp; Fusco, Alfredo; M., Santoro | |
| Different mutations of the RET gene cause different human tumoral diseases. | 1.1 Articolo in rivista | 1999 | Santoro, M.; Melillo, R. M.; Carlomagno, F.; Visconti, Roberta; DE VITA, Gabriella; Salvatore, Giuliana; Fusco, A.; Vecchio, Giancarlo | |
| Ret-mediated mitogenesis requires Src kinase activity. | 1.1 Articolo in rivista | 1999 | Melillo, R. M.; Barone, M. V.; Lupoli, Gelsy; Cirafici, A. M.; Carlomagno, F.; Visconti, Roberta; Matoskova, B.; DI FIORE, P. P.; Vecchio, Giancarlo; Fusco, A.; Santoro, M. | |
| Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret | 1.1 Articolo in rivista | 1998 | Chiariello, M; Visconti, R; Carlomagno, Francesca; Melillo, Rosa Marina; Bucci, C; De Franciscis, V; Fox, Gm; Jing, S; Coso, Om; Gutkind, Sj; Fusco, Alfredo; Santoro, M. | |
| Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). | 1.1 Articolo in rivista | 2003 | Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo | |
| The extent of linkage disequilibrium in four populations with distinct demographic histories | 1.1 Articolo in rivista | 2000 | Dunning, Am; Durocher, F; Healey, Cs; Teare, Md; Mcbride, Se; Carlomagno, Francesca; Xu, Cf; Dawson, E; Rhodes, S; Ueda, S; Lai, E; Luben, Rn; VAN RENSBURG, Ej; Mannermaa, A; Kataja, V; Rennart, G; Dunhami, ; Purvis, I; Easton, D; Ponder, Ba | |
| Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival | 1.1 Articolo in rivista | 2000 | De Vita, Gabriella; Melillo, Rosa Marina; Carlomagno, Francesca; Visconti, R; Castellone, Md; Bellacosa, A; Billaud, M; Fusco, Alfredo; Tsichlis, Pn; Santoro, M. | |
| Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease | 1.1 Articolo in rivista | 1998 | Carlomagno, F.; Melillo, Rosa Marina; Visconti, R.; Salvatore, G.; De Vita, Gabriella; Lupoli, G.; Yu, Y. B.; Jing, S. Q.; Vecchio, Giancarlo; Fusco, Alfredo; Santoro, M. | |
| Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer | 4.2 Abstract in Atti di convegno | 2012 | Gnanaprakasam, Krisnamoorthy; Guida, Teresa; Visciano, Carla; Liotti, Federica; Carlomagno, Francesca; Melillo, ROSA MARINA | |
| Molecular Mechianism of RET Activation In Human Neoplasia | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Santoro, Massimo; Carlomagno, F.; Melillo, ROSA MARINA; Vecchio, Giancarlo; Fusco, Alfredo | |
| Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas | 1.1 Articolo in rivista | 2003 | Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; Castellone, MARIA DOMENICA; Vitagliano, Donata; Guida, Teresa; Vecchio, Giancarlo; Fusco, Alfredo | |
| The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes | 1.1 Articolo in rivista | 2002 | Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Napolitano, M.; Vecchio, Giancarlo; Fusco, Alfredo; Gazit, A.; Levitzki, A.; Santoro, Massimo | |
| Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. | 1.1 Articolo in rivista | 2006 | Iavarone, C; Acunzo, M; Carlomagno, Francesca; Catania, A; Melillo, ROSA MARINA; Carlomagno, MARIA STELLA; Santoro, Massimo; Chiariello, M. | |
| RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. | 1.1 Articolo in rivista | 1998 | G., Tallini; Santoro, Massimo; M., Helie; Carlomagno, Francesca; G., Salvatore; G., Chiappetta; M. L., Carcangiu; Fusco, Alfredo | |
| Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. | 1.1 Articolo in rivista | 1993 | M., Santoro; N., Sabino; Y., Ishizaka; T., Ushijima; Carlomagno, Francesca; A., Cerrato; M., Grieco; C., Battaglia; M. L., Martelli; C., Paulin | |
| RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE | 1.1 Articolo in rivista | 1992 | Santoro, Massimo; Carlomagno, Francesca; Hay, I. D.; Herrmann, M. A.; Grieco, M.; Melillo, ROSA MARINA; Pierotti, M. A.; Bongarzone, I.; DELLA PORTA, G.; Berger, N.; Peix, J. L.; Paulin, C.; Fabien, N.; Vecchio, Giancarlo; Jenkins, R. B.; Fusco, Alfredo | |
| Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. | 1.1 Articolo in rivista | 2003 | Ciardiello, F; Caputo, R; Damiano, Vincenzo; Caputo, R; Troiani, T; Vitagliano, D; Carlomagno, F; Veneziani, BIANCA MARIA; Fontanini, G; Bianco, Ar; Tortora, Giampaolo | |
| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. | 1.1 Articolo in rivista | 2003 | Fortunato, Ciardiello; Rosa, Caputo; Vincenzo, Damiano; Roberta, Caputo; Teresa, Troiani; Donatella, Vitagliano; Carlomagno, Francesca; Veneziani, BIANCA MARIA; Gabriella, Fontanini; A., Raffaele Bianco; Giampaolo, Tortora |